Helicobacter pylori is a small, gram-negative microaerophilic bacterium that regularly colonize, inhabit and persist in the mucus layer of the human stomach. More than 20 species of Helicobacter has been recognized. It causes a chronic low-level inflammation of the stomach lining and is strongly linked to the development of duodenal and gastric ulcers and stomach cancer. More than 50% of the world''s population harbor Helicobacter pylori in their upper gastrointestinal tract. Infection is more prevalent in developing countries, and incidence is decreasing in developed countries. Emerging antibiotic resistance has consequences a major problem for the efficacy of treatment. Hence, research in Helicobacter pylori epidemiology and its associated diseases is therefore important for the development of novel treatment strategies and prevention Materials and methods A study was conducted to evaluate the efficacy of Pylorex plus, a herbal formulation for the treatment of Helicobacter pylori infection as compared to Quadruple allopathic therapy (Omeprazol, Amoxicillin, Metronidazol and Bismuth compounds). The therapeutic evaluations of these medicines were conducted on 176 clinically and immunologically diagnosed cases of Helicobacter pylori infection. All the patients selected for the study were thoroughly examined and clinical history was recorded in the prescribed proforma of case sheet enclosed herewith the thesis. The therapeutic evaluation of the drug was made on the basic improvement in the subjective signs and symptoms, clinical observations and pathological investigations at periodic intervals during the course of treatment. This data was collected in the period April 2010-March 2012 and completed the clinical trials.